📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: TargImmune

1.1 - Company Overview

TargImmune Logo

TargImmune

Headquarter: Switzerland
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of novel targeted onco-immunotherapies via its CTPIC non-viral vector platform to target and destroy receptor-overexpressing cancer cells. Offers the Ta:RNA platform using targeted nanoparticles to deliver synthetic double-stranded RNA (Poly-IC) to induce apoptosis and immune modulation. Pipeline includes TAR001 for EGFR-positive solid cancers advancing to clinical trials and TAR002 in preclinical for other solid tumor receptors.

Products and services

  • TAR001: Lead EGFR-targeted drug candidate for solid cancers, engineered to engage epidermal growth factor receptors (EGFR) and currently progressing toward clinical trials
  • Ta:RNA Platform: Non-viral platform using targeted nanoparticles to deliver synthetic double-stranded RNA (Poly-IC) into receptor-overexpressing cancer cells, inducing apoptosis and immune modulation in solid tumors
  • TAR002: Ta:RNA-based compound in pre-clinical development designed to target different receptors in solid tumors, part of the Ta:RNA-based portfolio

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to TargImmune

Acerta Pharma Logo

Acerta Pharma

HQ: United States Website
  • Description: Provider of oncology and autoimmune drug discovery and development, including CALQUENCE (acalabrutinib) for CLL; collaborative small-molecule discovery for hematologic malignancies; innovative clinical studies; resistance biology research using multi-omic profiling; R&D on target identification and optimization; and partnering and in-licensing opportunities.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Acerta Pharma company profile →
AroCell Logo

AroCell

HQ: Sweden Website
  • Description: Provider of biomarker-based diagnostic tests for cancer prognosis, monitoring, and follow-up, including the TK 210 ELISA measuring TK1 as a marker of increased cell turnover. Offers Oncology Diagnostics tools to capture critical clinical data for cancer patient management, and TUBEX TF, a rapid, sensitive in vitro test for detecting acute typhoid fever caused by Salmonella enterica.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full AroCell company profile →
Bellwether Bio Logo

Bellwether Bio

HQ: United States Website
  • Description: Provider of novel cell-free DNA-based diagnostic technologies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Bellwether Bio company profile →
Eikonoklastes Logo

Eikonoklastes

HQ: United States Website
  • Description: Provider of gene therapies that increase Caveolin-1 expression in neurons to address neurodegenerative diseases, including ET-101, designed to overexpress Caveolin-1 and potentially benefit patients with ALS, Parkinson’s, Huntington’s, MS, and dementia, and SynCav1, which enhances neuroprotection and neuroplasticity for a wide range of neurodegenerative conditions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Eikonoklastes company profile →
Novigenix Logo

Novigenix

HQ: Switzerland Website
  • Description: Provider of ImmunoTranscriptomic precision medicine solutions for disease detection, therapy optimization, and recurrence monitoring. Swiss company offering the LITOseek AI/RNA platform for immune response profiling, biomarker discovery, drug target discovery, and therapy response prediction; COLOX blood test for early colorectal cancer and pre-cancerous lesions; immunotherapy response prediction; digital cytometry; biomarker testing services.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Novigenix company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for TargImmune

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to TargImmune

2.2 - Growth funds investing in similar companies to TargImmune

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for TargImmune

4.2 - Public trading comparable groups for TargImmune

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to TargImmune

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About TargImmune

What does TargImmune do?

TargImmune is a provider of novel targeted onco-immunotherapies via its CTPIC non-viral vector platform to target and destroy receptor-overexpressing cancer cells. Offers the Ta:RNA platform using targeted nanoparticles to deliver synthetic double-stranded RNA (Poly-IC) to induce apoptosis and immune modulation. Pipeline includes TAR001 for EGFR-positive solid cancers advancing to clinical trials and TAR002 in preclinical for other solid tumor receptors.

Who are TargImmune's competitors?

TargImmune's competitors and similar companies include Acerta Pharma, AroCell, Bellwether Bio, Eikonoklastes, and Novigenix.

Where is TargImmune headquartered?

TargImmune is headquartered in Switzerland.

How many employees does TargImmune have?

TargImmune has 1,000 employees 🔒.

When was TargImmune founded?

TargImmune was founded in 2010 🔒.

What sector and industry vertical is TargImmune in?

TargImmune is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for TargImmune

Who are the top strategic acquirers in TargImmune's sector and industry

Top strategic M&A buyers and acquirers in TargImmune's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for TargImmune?

Top strategic M&A buyers groups and sectors for TargImmune include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in TargImmune's sector and industry vertical

Which are the top PE firms investing in TargImmune's sector and industry vertical?

Top PE firms investing in TargImmune's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in TargImmune's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in TargImmune's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in TargImmune's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to TargImmune include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in TargImmune's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for TargImmune?

The key public trading comparables and valuation benchmarks for TargImmune include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for TargImmune for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for TargImmune with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in TargImmune's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for TargImmune with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in TargImmune's' sector and industry vertical?

Access recent funding rounds and capital raises in TargImmune's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for TargImmune